Multiple sclerosis documentation system (MSDS): Moving from documentation to management of MS patients

Journal of Neural Transmission

Volumn 120, Issue SUPPL. 1, 2013, Pages

  Ziemssen, Tjalf ^a   Kempcke, Raimar ^a   Eulitz, Marco ^a   Großmann, Lars ^a   Suhrbier, Alexander ^a   Thomas, Katja ^a   Schultheiss, Thorsten ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Database; Management; Multiple sclerosis; Multiple sclerosis documentation system

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

CLINICAL PRACTICE; CLINICAL RESEARCH; HUMAN; INTERNET; MEDICAL DOCUMENTATION; MEDICAL INFORMATION SYSTEM; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS DOCUMENTATION SYSTEM; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TOTAL QUALITY MANAGEMENT;

DATABASES, FACTUAL; DOCUMENTATION; HUMANS; MULTIPLE SCLEROSIS;

EID: 84892801642     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1041-x     Document Type: Review

References (29)

1. Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T (2010) Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 68(3): 409-411
2. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359(9313):1221-1231
3. Confavreux C, Paty DW (1995) Current status of computerization of multiple sclerosis clinical data for research in Europe and North America: the EDMUS/MS-COSTAR connection. European database for multiple sclerosis. Multiple sclerosis-computed stored ambulatory record. Neurology 45(3 Pt 1):573-576
4. Evans C, Tam J, Kingwell E, Oger J, Tremlett H (2012) Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther 34(2): 341-350
5. Flachenecker P, Zettl UK, Gotze U, Haas J, Schimrigk S, Elias W, Pette M, Eulitz M, Hennig M, Bertram J, Hollweck R, Neiss A, Daumer M, Pitschnau-Michel D, Rieckmann P (2005) MS registry in Germany-design and first results of the pilot phase. Der Nervenarzt 76(8):967-975
6. Fugger L, Friese MA, Bell JI (2009) From genes to function: the next challenge to understanding multiple sclerosis. Nat Rev Immunol 9(6):408-417
7. Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C (2013) Advances in the treatment of relapsing-remitting multiple sclerosis- critical appraisal of fingolimod. Ther Clin Risk Manag 9:73-85
8. Giovannoni G, Kinkel P, Vartanian T (2007) Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Rev Neurol Dis 4(4):184-193
9. Haase R, Schultheiss T, Kempcke R, Thomas K, Ziemssen T (2012) Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study. J Med Internet Res 14(5):e135
10. Haase R, Schultheiss T, Kempcke R, Thomas K, Ziemssen T (2013) Modern communication technology skills of patients with multiple sclerosis. Mult Scler [Epub ahead of print]
11. Kempcke R, Schultheiss T, Kratzsch F, Eulitz M, Reichmann H, Ziemssen T (2012a) Modern therapy management for the improvement of the therapy with interferon beta-1b with MSDS 3D. Aktuelle Neurol 39:S2-S5
12. Kempcke R, Schultheiss T, Ziemssen T (2012b) Advances in MS patient management: update of Multiple Sclerosis Documentation System 'MSDS 3D'. Eur J Neurol 19:710
13. Kratzsch F, Eulitz M, Kempcke R, Lorz A, Meissner K, Ziemssen T (2009) Development of the multidimensional (physician, nurse, patient) multiple sclerosis documentation system "MSDS 3D". Mult Scler 15(9):S55-S55
14. Lugaresi A, Ziemssen T, Oreja-Guevara C, Thomas D, Verdun E (2012) Improving patient-physician dialog: commentary on the results of the MS Choices survey. Patient Prefer Adherence 6:143-152
15. MacLean R (2004) The challenge of managing patients with multiple sclerosis. Nurs Times 100(4):42-44
16. Pette M, Eulitz M (2002) The Multiple sclerosis documentation system MSDS. Discussion of a documentation standard for multiple sclerosis. Der Nervenarzt 73(2):144-148
17. Pette M, Zettl UK (2002) The use of multiple sclerosis databases at neurological university hospitals in Germany. Mult Scler 8(3):265-267
18. Schultheiss T, Kempcke R, Kratzsch F, Eulitz M, Pette M, Reichmann H, Ziemssen T (2012a) Multiple sclerosis management system 3D. Moving from documentation towards management of patients. Der Nervenarzt 83(4):450-457
19. Schultheiss T, Kempcke R, Ziemssen T (2012b) Innovative management of MS patients on natalizumab using MSDS 3D software. J Neurol 259:S109
20. Sobek S, Kempcke R, Ziemssen T, Schultheiss T (2012) Impact of fampridine on fatigue, depression and cognition in multiple sclerosis. Eur J Neurol 19:354
21. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5):278-285
22. Whitaker JN, Mitchell GW, Cutter GR (1995) Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis. Ann Neurol 37(1):5-6
23. Ziemssen T (2009) Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 277(Suppl 1):S37-S41
24. Ziemssen T (2011) Symptom management in patients with multiple sclerosis. J Neurol Sci 311(S1):S48-S52
25. Ziemssen T, Kratzsch F, Eulitz M, Kempcke R, Kleiner N (2010a) Development and first evaluation of the new patient management and documentation system MSDS 3D for patients with multiple sclerosis. Neurology 74(9):A554
26. Ziemssen T, Kratzsch F, Kempcke R (2010b) Patient management of MS patients on natalizumab therapy with MSDS 3D. Nervenheilkunde 29:S31-S33
27. Ziemssen T, van Lokven T, Kempcke R, Meergans M (2012a) Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya (R)) in multiple sclerosis patients in Germany (PANGAEA). J Neurol 259:S72
28. Ziemssen T, van Lokven T, Kempke R, Meergans M (2012b) Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya (R)) in multiple sclerosis patients in Germany (PANGAEA). Neurology 78:A332
29. Ziemssen T, van Lokven T, Ortler S, Meergans M (2012c) Changes in current evaluation of new drugs needs survey of pharmaeconomic data: treatment satisfaction of fingolimod (Gilenya) in comparison to first-line-therapeutics in multiple sclerosis patients (PANGAEA and PEARL). Aktuelle Neurol 39(7):385